在人类P2X4受体上发现了antraquinones的全结合部位
Jessica Nagel1, Vigneshwaran Namasivayam1, Stephanie Weinhausen1
1Pharmaceutical & Medicinal Chemistry, PharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Bonn, Germany.
Nature communications
|December 4, 2025
概括
研究人员确定了P2X4受体的关键相互作用,这对于开发针对炎症疾病和疼痛的新药至关重要. 修改特定的氨基酸显著提高了药物的效力.
科学领域:
- 分子药理学和结构生物学.
- 离子通道研究
- 药物发现 药物发现
背景情况:
- P2X受体是三元ATP受体的离子通道.
- P2X4受体亚型是炎症性疾病,神经病痛和癌症的重要治疗点.
研究的目的:
- 研究作为P2X4受体调节剂的 antraquinone衍生物的结构-活性关系.
- 为了确定P2X4受体对抗剂的全结合部位和关键相互作用残留物.
主要方法:
- 使用了嵌合体受体方法,突变发生和分子对接研究.
- 确定了与PSB-0704.4复合的人类P2X4-E307T受体的冷电子显微镜结构.
主要成果:
- 在P2X4受体的上体中确定了Glu307,作为形成"离子锁"的残留物,阻碍了高 afinity anthraquinone 的结合.
- 将Glu307转变为氨酸 (P2X4-E307T) 显著增加了antraquinones在阻断P2X4受体功能的功效.
- 在受体上体中的三元子单元接口上发现了一个新的全结合部位.
结论:
- Glu307残留物及其相互作用对基于 antraquinone 的 P2X4 受体对抗剂的疗效至关重要.
- 已确定的全位和结构为基于结构的药物设计提供了强效和选择性的P2X4受体抑制剂的基础.
相关概念视频
Allosteric Proteins-ATCase
6.4K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.4K
Ligand Binding and Linkage
5.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.4K
Adrenergic Receptors: ɑ Subtype
2.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.6K
GPCRs Regulate Adenylyl Cylase Activity
7.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.2K
Allosteric Regulation
62.8K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
62.8K
Drug-Receptor Interaction: Agonist
3.7K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.7K


